Clinical Trial Update: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating JMT101 in combination with osimertinib for locally advanced or metastatic non-small cell lung cancer with EGFR common mutations; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JMT101
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING